| Bris<SPAN style="FONT-SIZE: medium">tol-Myers Squibb (BMY)与Otsuka Pharmaceutical宣布，美国FDA通过ABILIFY(阿立哌唑)新药上市申请补件(sNDA)，治疗6-17岁自闭症儿童与青少年的异常情绪。</SPAN>
<P><SPAN style="FONT-SIZE: medium">ABILIFY相关信息:</SPAN></P>
<P><SPAN style="FONT-SIZE: medium">1.ABILIFY合成路线<A href="http://www.chemdrug.com/databases/8_0_voahkbjcodpftwlj.html"><FONT color=#0000ff>http://www.chemdrug.com/databases/8_0_voahkbjcodpftwlj.html</FONT></A></SPAN></P>
<P><SPAN style="FONT-SIZE: medium">2.神经系统用药——BMS与大塜公司推出Abilify新剂型</SPAN></P>
<P><SPAN style="FONT-SIZE: medium"><A href="http://www.chemdrug.com/databases/7_6_udafpleojbxufvpv.html"><FONT color=#0000ff>http://www.chemdrug.com/databases/7_6_udafpleojbxufvpv.html</FONT></A></SPAN></P>
<P><SPAN style="FONT-SIZE: medium">3.简述新型抗精神病药阿立哌唑</SPAN></P>
<P><SPAN style="FONT-SIZE: medium"><A href="http://www.chemdrug.com/databases/7_4_kjaxinyerriupnac.html"><FONT color=#0000ff>http://www.chemdrug.com/databases/7_4_kjaxinyerriupnac.html</FONT></A></SPAN></P>
<P><SPAN style="FONT-SIZE: medium">4.阿立哌唑治疗精神分裂症的临床评价</SPAN></P>
<P><SPAN style="FONT-SIZE: medium"><A href="http://www.chemdrug.com/databases/7_13_apetaawdnesyhacr.html"><FONT color=#0000ff>http://www.chemdrug.com/databases/7_13_apetaawdnesyhacr.html</FONT></A></SPAN></P>
<P><SPAN style="FONT-SIZE: medium">5.阿立哌唑治疗慢性精神分裂症效果评价</SPAN></P>
<P><SPAN style="FONT-SIZE: medium"><A href="http://www.chemdrug.com/databases/7_2_ptswyflhtcvxjxrp.html"><FONT color=#0000ff>http://www.chemdrug.com/databases/7_2_ptswyflhtcvxjxrp.html</FONT></A></SPAN></P>
<P><SPAN style="FONT-SIZE: medium">6.阿立哌唑与利培酮治疗精神分裂症的对照研究</SPAN></P>
<P><SPAN style="FONT-SIZE: medium"><A href="http://www.chemdrug.com/databases/7_8_igsytqgdclwmknwc.html"><FONT color=#0000ff>http://www.chemdrug.com/databases/7_8_igsytqgdclwmknwc.html</FONT></A> </SPAN></P> |
